BioXcel Therapeutics (FRA:BX2) Beginning Cash Position : €60.00 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Beginning Cash Position?

BioXcel Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2024 was €60.00 Mil.

BioXcel Therapeutics's quarterly Beginning Cash Position declined from Sep. 2023 (€119.51 Mil) to Dec. 2023 (€82.49 Mil) and declined from Dec. 2023 (€82.49 Mil) to Mar. 2024 (€60.00 Mil).

BioXcel Therapeutics's annual Beginning Cash Position increased from Dec. 2021 (€188.61 Mil) to Dec. 2022 (€219.92 Mil) but then declined from Dec. 2022 (€219.92 Mil) to Dec. 2023 (€177.65 Mil).

BioXcel Therapeutics Beginning Cash Position Historical Data

The historical data trend for BioXcel Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Beginning Cash Position Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

38.31

26.66

188.61

219.92

177.65

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															180.94	152.78	119.51	82.49	60.00

BioXcel Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

BioXcel Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines